Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II exploratory ascending dose study of BIM23A760 in acromegalic patients
2008-000500-83Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jun 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of onzigolide in acromegaly, sponsored by Ipsen. Primary endpoint: Maximum observed % inhibition of growth hormone (GH). Started Jun 2008; status: completed.
02
Drugs
onzigolide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2008-000500-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000500-83.